Thiazolidinediones, dyslipidaemia and insulin resistance syndrome

被引：22

作者：

Sunayama, S ^{[1
]}

Watanabe, Y ^{[1
]}

Daida, H ^{[1
]}

Yamaguchi, H ^{[1
]}

机构：

[1] Juntendo Univ, Dept Cardiol, Bunkyo Ku, Tokyo 1138421, Japan

来源：

CURRENT OPINION IN LIPIDOLOGY | 2000年 / 11卷 / 04期

关键词：

D O I：

10.1097/00041433-200008000-00009

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Insulin resistance is known to unite several metabolic abnormalities. The associated dyslipidaemia appears to play a central role in this atherogenic syndrome. Thiazolidinediones, which are recently introduced insulin sensitizing agents, have been shown to be effective not only in reducing elevated glucose levels, but also in improving the other metabolic abnormalities that are associated with insulin resistance. The present review focuses on these potential effects of thiazolidinediones. Curr Opin Lipidol 11:397-402. (C) 2000 Lippincott Williams & Wilkins.

引用

页码：397 / 402

页数：6

共 89 条

[1] Al-Salman J, 2000, ANN INTERN MED, V132, P121, DOI 10.7326/0003-4819-132-2-200001180-00006
[2] Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone
Antonucci, T
Whitcomb, R
McLain, R
Lockwood, D
[J]. DIABETES CARE, 1997, 20 (02) : 188 - 193
[3] ATHEROGENIC LIPOPROTEIN PHENOTYPE - A PROPOSED GENETIC-MARKER FOR CORONARY HEART-DISEASE RISK
AUSTIN, MA
KING, MC
VRANIZAN, KM
KRAUSS, RM
[J]. CIRCULATION, 1990, 82 (02) : 495 - 506
[4] Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes
Austin, MA
Edwards, KL
[J]. CURRENT OPINION IN LIPIDOLOGY, 1996, 7 (03) : 167 - 171
[5] Leptin
Auwerx, J
Staels, B
[J]. LANCET, 1998, 351 (9104) : 737 - 742
[6] Bray GA, 1999, DIABETES CARE, V22, P623
[7] Troglitazone action is independent of adipose tissue
Burant, CF
Sreenan, S
Hirano, KI
Tai, TAC
Lohmiller, J
Lukens, J
Davidson, NO
Ross, S
Graves, RA
[J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (11) : 2900 - 2908
[8] Troglitazone use in insulin-treated type 2 diabetic patients
Buse, JB
Gumbiner, B
Mathias, NP
Nelson, DM
Faja, BW
Whitcomb, RW
[J]. DIABETES CARE, 1998, 21 (09) : 1455 - 1461
[9] Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers
Cominacini, L
Young, MMR
Capriati, A
Garbin, U
Fratta Pasini, A
Campagnola, M
Davoli, A
Rigoni, A
Contessi, GB
LoCascio, V
[J]. DIABETOLOGIA, 1997, 40 (10) : 1211 - 1218
[10] Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells
Cominacini, L
Garbin, U
Pastorino, AM
Campagnola, M
Fratta Pasini, A
Davoli, A
Rigoni, A
LoCascio, V
[J]. DIABETOLOGIA, 1997, 40 (02) : 165 - 172

← 1 2 3 4 5 6 7 8 9 →